Pharmacological management of co-morbid obstructive sleep apnoea and insomnia

References

• Benjafield AV, Ayas NT, Eastwood PR, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019 Aug;7(8):687–698. doi: 10.1016/S2213-2600(19)30198-5
   PubMed Web of Science ®Google Scholar
• Lechat B, Naik G, Reynolds A, et al. Multinight Prevalence, variability, and diagnostic misclassification of obstructive sleep apnea. Am J Respir Crit Care Med. 2022 Mar 1;205(5):563–569. doi: 10.1164/rccm.202107-1761OC
   PubMed Web of Science ®Google Scholar
• Roth T, Coulouvrat C, Hajak G, et al. Prevalence and perceived health associated with insomnia based on DSM-IV-TR; international statistical classification of diseases and related health problems, tenth revision; and research diagnostic criteria/international classification of sleep disorders, second edition criteria: results from the America insomnia survey. Biol Psychiatry. 2011 Mar 15;69(6):592–600. doi: 10.1016/j.biopsych.2010.10.023
   PubMed Web of Science ®Google Scholar
• Hafner M, Romanelli RJ, Yerushalmi E, et al. The societal and economic burden of insomnia in adults: an international study. Santa Monica (CA): RAND Corporation; 2023.
   Google Scholar
• Senaratna CV, Perret JL, Lodge CJ, et al. Prevalence of obstructive sleep apnea in the general population: a systematic review. Sleep Med Rev. 2017 Aug;34:70–81.
   PubMed Web of Science ®Google Scholar
• Roth T. Insomnia: definition, Prevalence, etiology, and consequences. J Clin Sleep Med. 2007;3(5 suppl):S7–S10. doi: 10.5664/jcsm.26929
   PubMed Web of Science ®Google Scholar
• Pepin JL, Eastwood P, Eckert DJ. Novel avenues to approach non-CPAP therapy and implement comprehensive obstructive sleep apnoea care. Eur Respir J. 2022 Jun;59(6):2101788. doi: 10.1183/13993003.01788-2021
   PubMed Web of Science ®Google Scholar
• Hamilton G, Li Chai-Coetzer C. Update on the assessment and investigation of adult obstructive sleep apnoea. Aust J Gen Pract. 2019;48:176–181. doi: 10.31128/AJGP-12-18-4777
   PubMed Web of Science ®Google Scholar
• Sateia M. International classification of sleep disorders-third edition. Chest. 2014;146:1387–94. doi: 10.1378/chest.14-0970
   PubMed Web of Science ®Google Scholar
• Pagel JF, Pandi-Perumal SR, Monti JM. Treating insomnia with medications. Sleep Sci pract. 2018;2(1):5. doi: 10.1186/s41606-018-0025-z
   Google Scholar
• American Psychiatric Association. Section II: Diagnostic criteria and codes. Sleep-Wake Disorders. Diagnostic and Statistical Manual of Mental Disorders. DSM Library: American Psychiatric Association Publishing; 2022. doi: 10.1176/appi.books.9780890425787.x12_Sleep-Wake_Disorders
   Google Scholar
• Martucci M, Conte M, Ostan R, et al. Both objective and paradoxical insomnia elicit a stress response involving mitokine production. Aging. 2020 May 17;12(11):10497–10505. doi: 10.18632/aging.103274
   PubMedGoogle Scholar
• Grima N, Bei B, Mansfield D. Insomnia theory and assessment. Aust J Gen Pract. 2019;48(4):193–197. doi: 10.31128/AJGP-12-18-4780
   PubMed Web of Science ®Google Scholar
• Sweetman A, Lack L, Bastien C. Co-Morbid Insomnia and Sleep Apnea (COMISA): prevalence, consequences, methodological considerations, and recent randomized controlled trials. Brain Sci. 2019 Dec 12;9(12):371. doi: 10.3390/brainsci9120371
   PubMed Web of Science ®Google Scholar
• Sweetman A, Lack L, Crawford M, et al. Comorbid insomnia and sleep apnea: assessment and management approaches. Sleep Med Clin. 2022 Dec;17(4):597–617. doi: 10.1016/j.jsmc.2022.07.006
   PubMed Web of Science ®Google Scholar
• Finkel KJ, Searleman AC, Tymkew H, et al. Prevalence of undiagnosed obstructive sleep apnea among adult surgical patients in an academic medical center. Sleep Med. 2009 Aug;10(7):753–758. doi: 10.1016/j.sleep.2008.08.007
   PubMed Web of Science ®Google Scholar
• Sweetman A, Melaku YA, Lack L, et al. Prevalence and associations of co-morbid insomnia and sleep apnoea in an Australian population-based sample. Sleep Med. 2021 Jun;82:9–17.
   PubMed Web of Science ®Google Scholar
• Sweetman A, Lack L, McEvoy RD, et al. Bi-directional relationships between co-morbid insomnia and sleep apnea (COMISA). Sleep Med Rev. 2021 Dec;60:101519.
   PubMed Web of Science ®Google Scholar
• Lang CJ, Appleton SL, Vakulin A, et al. Co-morbid OSA and insomnia increases depression prevalence and severity in men. Respirology. 2017 Oct;22(7):1407–1415. doi: 10.1111/resp.13064
   PubMed Web of Science ®Google Scholar
• Wickwire EM, Jobe SL, Oldstone LM, et al. Lower socioeconomic status and co-morbid conditions are associated with reduced continuous positive airway pressure adherence among older adult medicare beneficiaries with obstructive sleep apnea. Sleep. 2020;43(12). doi: 10.1093/sleep/zsaa122
   Web of Science ®Google Scholar
• Wickwire EM. Value-based sleep and breathing: health economic aspects of obstructive sleep apnea. Fac Rev. 2021;10:40. doi: 10.12703/r/10-40
   PubMedGoogle Scholar
• Streatfeild J, Smith J, Mansfield D, et al. The social and economic cost of sleep disorders. Sleep. 2021 Nov 12;44(11). doi: 10.1093/sleep/zsab132
   PubMed Web of Science ®Google Scholar
• Lechat B, Loffler KA, Wallace DM, et al. All-cause mortality in people with co-occurring insomnia symptoms and sleep apnea: analysis of the Wisconsin sleep cohort. Nat Sci Sleep. 2022;14:1817–1828. doi: 10.2147/NSS.S379252
   PubMed Web of Science ®Google Scholar
• Sweetman A, Farrell S, Wallace DM, et al. The effect of cognitive behavioural therapy for insomnia in people with comorbid insomnia and sleep apnoea: a systematic review and meta-analysis. J Sleep Res. 2023;32:e13847.
   PubMed Web of Science ®Google Scholar
• Lechat B, Appleton S, Melaku YA, et al. Comorbid insomnia and sleep apnoea is associated with all-cause mortality. Eur Respir J. 2022 Jul;60(1):2101958. doi: 10.1183/13993003.01958-2021
   PubMed Web of Science ®Google Scholar
• Lechat B, Appleton S, Melaku YA, et al. The association of co-morbid insomnia and sleep apnea with prevalent cardiovascular disease and incident cardiovascular events. J Sleep Res. 2022;31(5):e13563. doi: 10.1111/jsr.13563
   PubMed Web of Science ®Google Scholar
• Eckert DJ. Phenotypic approaches to obstructive sleep apnoea - New pathways for targeted therapy. Sleep Med Rev. 2018 Feb;37:45–59. doi: 10.1016/j.smrv.2016.12.003
   PubMed Web of Science ®Google Scholar
• Altree TJ, Eckert DJ. Obstructive sleep apnea endotypes and their postoperative relevance. Int Anesthesiol Clin. 2022 Apr 1;60(2):1–7. doi: 10.1097/AIA.0000000000000357
   PubMed Web of Science ®Google Scholar
• Eckert DJ, White DP, Jordan AS, et al. Defining phenotypic causes of obstructive sleep apnea. Identification of novel therapeutic targets. Am J Respir Crit Care Med. 2013 Oct 15;188(8):996–1004. doi: 10.1164/rccm.201303-0448OC
   PubMed Web of Science ®Google Scholar
• Osman AM, Carter SG, Carberry JC, et al. Obstructive sleep apnea: current perspectives. Nat Sci Sleep. 2018;10:21–34. doi: 10.2147/NSS.S124657
   PubMed Web of Science ®Google Scholar
• Bonnet MH. Hyperarousal and insomnia. Sleep Med Rev. 2010 Feb;14(1):33. doi: 10.1016/j.smrv.2009.07.003
   PubMed Web of Science ®Google Scholar
• Perlis M, Pigeon W, Gehrman P, et al. Neurobiological Mechanisms In Chronic Insomnia. Sleep Med Clin. 2009 Dec;4(4):549–558. doi: 10.1016/j.jsmc.2009.07.002
   PubMedGoogle Scholar
• Corsi-Cabrera M, Figueredo-Rodríguez P, Del Río-Portilla Y, et al. Enhanced frontoparietal synchronized activation during the wake-sleep transition in patients with primary insomnia. Sleep. 2012 Apr 1;35(4):501–511. doi: 10.5665/sleep.1734
   PubMed Web of Science ®Google Scholar
• Lack LC, Micic G, Lovato N. Circadian aspects in the aetiology and pathophysiology of insomnia. J Sleep Res. 2023 Aug 3;32(6):e13976.
   PubMedGoogle Scholar
• Yanagimori M, Fernandes MD, Garcia ML, et al. Respiratory arousal threshold among patients with isolated sleep apnea and with comorbid insomnia (COMISA). Sci Rep. 2023;13(1). doi: 10.1038/s41598-023-34002-4
   PubMed Web of Science ®Google Scholar
• Zinchuk A, Edwards BA, Jeon S, et al. Prevalence, associated clinical features, and impact on continuous positive airway pressure use of a low respiratory arousal threshold among male United States veterans with obstructive sleep apnea. J Clin Sleep Med. 2018 May 15;14(5):809–817. doi: 10.5664/jcsm.7112
   PubMed Web of Science ®Google Scholar
• Zinchuk AV, Chu JH, Liang J, et al. Physiological traits and adherence to sleep apnea therapy in individuals with coronary artery disease. Am J Respir Crit Care Med. 2021 Sep 15;204(6):703–712. doi: 10.1164/rccm.202101-0055OC
   PubMed Web of Science ®Google Scholar
• Ong JC, Crawford MR, Wallace DM. Sleep Apnea and Insomnia: Emerging Evidence for Effective Clinical Management. Chest. 2021 May;159(5):2020–2028. doi: 10.1016/j.chest.2020.12.002
   PubMed Web of Science ®Google Scholar
• Gupta MA, Simpson FC. Obstructive sleep apnea and psychiatric disorders: a systematic review. J Clin Sleep Med. 2015 Jan 15;11(2):165–175. doi: 10.5664/jcsm.4466
   PubMed Web of Science ®Google Scholar
• Ragnoli B, Pochetti P, Raie A, et al. Comorbid Insomnia and Obstructive Sleep Apnea (COMISA): Current Concepts of Patient Management. Int J Environ Res Public Health. 2021 Sep 1;18(17):9248. doi: 10.3390/ijerph18179248
   PubMed Web of Science ®Google Scholar
• Iftikhar IH, Bittencourt L, Youngstedt SD, et al. Comparative efficacy of CPAP, MADs, exercise-training, and dietary weight loss for sleep apnea: a network meta-analysis. Sleep Med. 2017 Feb;30:7–14.
   PubMed Web of Science ®Google Scholar
• Pataka A, Kotoulas SC, Gavrilis PR, et al. Adherence to CPAP treatment: can mindfulness play a role? Life. 2023;13(2):296. doi: 10.3390/life13020296
   PubMedGoogle Scholar
• Srijithesh PR, Aghoram R, Goel A, et al. Positional therapy for obstructive sleep apnoea. Cochrane Database Of Systematic Reviews. 2019 May 1;2019(11):CD010990. doi: 10.1002/14651858.CD010990.pub2
   Google Scholar
• Sarkissian L, Kitipornchai L, Cistulli P, et al. An update on the current management of adult obstructive sleep apnoea. Aust J Gen Pract. 2019;48(4):182–186. doi: 10.31128/AJGP-10-18-4749
   PubMed Web of Science ®Google Scholar
• Chapman JL, Vakulin A, Hedner J, et al. Modafinil/armodafinil in obstructive sleep apnoea: a systematic review and meta-analysis. Eur Respir J. 2016;47(5):1420–1428. doi: 10.1183/13993003.01509-2015
   PubMed Web of Science ®Google Scholar
• Grima N, Bei B, Mansfield D. Insomnia management. Aust J Gen Pract. 2019 Mar 20;48(4):198–202.
   PubMed Web of Science ®Google Scholar
• Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017 Dec;26(6):675–700. doi: 10.1111/jsr.12594
   PubMed Web of Science ®Google Scholar
• Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017 Feb 15;13(2):307–349. doi: 10.5664/jcsm.6470
   PubMed Web of Science ®Google Scholar
• Rossman J. Cognitive-behavioral therapy for insomnia: an effective and underutilized treatment for insomnia. Am J Lifestyle Med. 2019 Nov;13(6):544–547. doi: 10.1177/1559827619867677
   PubMed Web of Science ®Google Scholar
• Xue T, Wu X, Chen S, et al. The efficacy and safety of dual orexin receptor antagonists in primary insomnia: a systematic review and network meta-analysis. Sleep Med Rev. 2022 Feb;61:101573.
   PubMed Web of Science ®Google Scholar
• Papillon-Ferland L, Mallet L. Should melatonin be used as a sleeping aid for elderly people? Can J Hosp Pharm. 2019 Jul;72(4):327–329. doi: 10.4212/cjhp.v72i4.2920
   PubMed Web of Science ®Google Scholar
• Gooneratne NS, Gehrman P, Gurubhagavatula I, et al. Effectiveness of ramelteon for insomnia symptoms in older adults with obstructive sleep apnea: a randomized placebo-controlled pilot study. J Clin Sleep Med. 2010;6(6):572–580. doi: 10.5664/jcsm.27991
   PubMed Web of Science ®Google Scholar
• Sweetman AM, Lack LC, Catcheside PG, et al. Developing a successful treatment for co-morbid insomnia and sleep apnoea. Sleep Med Rev. 2017 Jun;33:28–38.
   PubMed Web of Science ®Google Scholar
• Sweetman A, Lack L, McEvoy RD, et al. Cognitive behavioural therapy for insomnia reduces sleep apnoea severity: a randomised controlled trial. ERJ Open Res. 2020;6(2):00161–2020. doi: 10.1183/23120541.00161-2020
   PubMedGoogle Scholar
• Wang SH, Chen WS, Tang SE, et al. Benzodiazepines associated with acute respiratory failure in patients with obstructive sleep apnea. Front Pharmacol. 2018;9:1513. doi: 10.3389/fphar.2018.01513
   PubMed Web of Science ®Google Scholar
• Ekström MP, Bornefalk-Hermansson A, Abernethy AP, et al. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ. 2014 Jan 30;348(jan30 2):g445. doi: 10.1136/bmj.g445
   PubMedGoogle Scholar
• Carberry JC, Fisher LP, Grunstein RR, et al. Role of common hypnotics on the phenotypic causes of obstructive sleep apnoea: paradoxical effects of zolpidem. Eur Respir J. 2017;50(6):1701344. doi: 10.1183/13993003.01344-2017
   PubMed Web of Science ®Google Scholar
• Carter SG, Eckert DJ. Effects of hypnotics on obstructive sleep apnea endotypes and severity: novel insights into pathophysiology and treatment. Sleep Med Rev. 2021 Aug;58:101492. doi: 10.1016/j.smrv.2021.101492
   PubMed Web of Science ®Google Scholar
• Sun H, Palcza J, Card D, et al. Effects of suvorexant, an orexin receptor antagonist, on respiration during sleep in patients with obstructive sleep apnea. J Clin Sleep Med. 2016;12(1):9–17. doi: 10.5664/jcsm.5382
   PubMed Web of Science ®Google Scholar
• Cheng JY, Filippov G, Moline M, et al. Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: a randomized, double-blind, placebo-controlled, crossover study. J Sleep Res. 2020 Aug;29(4):e13021. doi: 10.1111/jsr.13021
   PubMed Web of Science ®Google Scholar
• Kushida C, Zammit G, Cheng J, et al. 0354 Effect of lemborexant on sleep architecture in subjects with comorbid insomnia and mild obstructive sleep apnea from a Ph 3 trial. Sleep. 2023;46(Supplement_1):A157–A157. doi: 10.1093/sleep/zsad077.0354
   Google Scholar
• Moline M, Cheng J, Kumar D, et al. Effect of lemborexant on sleep onset and maintenance in patients with comorbid insomnia disorder and mild obstructive sleep apnea (P4-13.001). Neurology. 2023;100(17 Supplement 2):2447.
   Web of Science ®Google Scholar
• Brandt J, Leong C. Benzodiazepines and Z-Drugs: an updated review of major adverse outcomes reported on in epidemiologic research. Drugs R D. 2017 Dec;17(4):493–507. doi: 10.1007/s40268-017-0207-7
   PubMed Web of Science ®Google Scholar
• Hsu TW, Chen HM, Chen TY, et al. The association between use of benzodiazepine receptor agonists and the risk of obstructive sleep apnea: a nationwide population-based nested case-control study. Int J Environ Res Public Health. 2021 Sep 15;18(18):9720. doi: 10.3390/ijerph18189720
   PubMed Web of Science ®Google Scholar
• De Crescenzo F, D’Alò GL, Ostinelli EG, et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. 2022 Jul 16;400(10347):170–184. doi: 10.1016/S0140-6736(22)00878-9
   PubMed Web of Science ®Google Scholar
• Uchiyama M, Sakamoto S, Miyata K. Effect of ramelteon on insomnia severity: evaluation of patient characteristics affecting treatment response. Sleep Biol Rhythms. 2019;17(4):379–388. doi: 10.1007/s41105-019-00224-1
   Web of Science ®Google Scholar
• Erman M, Seiden D, Zammit G, et al. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med. 2006 Jan;7(1):17–24. doi: 10.1016/j.sleep.2005.09.004
   PubMed Web of Science ®Google Scholar
• Arredondo E, Deleon M, Masozera I, et al. Overview of the role of pharmacological management of obstructive sleep apnea. Medicina. 2022;58(2):225. doi: 10.3390/medicina58020225
   PubMedGoogle Scholar
• Shi Q, Wang Y, Hao Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2022 Jan 15;399(10321):259–269. doi: 10.1016/S0140-6736(21)01640-8
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Verbraecken J, Partinen M, et al. Pitolisant for daytime sleepiness in patients with obstructive sleep apnea who refuse continuous positive airway pressure treatment. A randomized trial. Am J Respir Crit Care Med. 2020 May 1;201(9):1135–1145. doi: 10.1164/rccm.201907-1284OC
   PubMed Web of Science ®Google Scholar
• Ronnebaum S, Bron M, Patel D, et al. Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea. J Clin Sleep Med. 2021 Dec 1;17(12):2543–2555. doi: 10.5664/jcsm.9610
   PubMed Web of Science ®Google Scholar
• Altree TJ, Aishah A, Loffler KA, et al. The norepinephrine reuptake inhibitor reboxetine alone reduces obstructive sleep apnea severity: a double-blind, placebo-controlled, randomized crossover trial. J Clin Sleep Med. 2023 Jan 1;19(1):85–96. doi: 10.5664/jcsm.10256
   PubMed Web of Science ®Google Scholar
• Schweitzer PK, Taranto-Montemurro L, Ojile JM, et al. The combination of Aroxybutynin and atomoxetine in the treatment of obstructive sleep apnea (MARIPOSA): a randomized controlled trial. Am J Respir Crit Care Med. 2023 Oct 9. doi: 10.1164/rccm.202306-1036OC
   Google Scholar
• Lim R, Messineo L, Grunstein RR, et al. The noradrenergic agent reboxetine plus the antimuscarinic hyoscine butylbromide reduces sleep apnoea severity: a double-blind, placebo-controlled, randomised crossover trial. J Physiol. 2021 Sep;599(17):4183–4195. doi: 10.1113/JP281912
   PubMed Web of Science ®Google Scholar
• Aishah A, Lim R, Sands SA, et al. Different antimuscarinics when combined with atomoxetine have differential effects on obstructive sleep apnea severity. J Appl Physiol. 2021 May 1;130(5):1373–1382. doi: 10.1152/japplphysiol.01074.2020
   PubMed Web of Science ®Google Scholar
• Aishah A, Loffler KA, Toson B, et al. One month dosing of atomoxetine plus oxybutynin in obstructive sleep apnea: a randomized, placebo-controlled trial. Ann Am Thorac Soc. 2023 Apr;20(4):584–595. doi: 10.1513/AnnalsATS.202206-492OC
   PubMed Web of Science ®Google Scholar
• Perger E, Taranto Montemurro L, Rosa D, et al. Reboxetine plus oxybutynin for OSA treatment. Chest. 2022;161(1):237–247. doi: 10.1016/j.chest.2021.08.080
   PubMed Web of Science ®Google Scholar
• Carberry JC, Grunstein RR, Eckert DJ. The effects of zolpidem in obstructive sleep apnea - An open-label pilot study. J Sleep Res. 2019 Dec;28(6):e12853. doi: 10.1111/jsr.12853
   PubMed Web of Science ®Google Scholar
• Carter SG, Berger MS, Carberry JC, et al. Zopiclone increases the arousal threshold without impairing genioglossus activity in obstructive sleep apnea. Sleep. 2016;39(4):757–766. doi: 10.5665/sleep.5622
   PubMed Web of Science ®Google Scholar
• Carter SG, Carberry JC, Grunstein RR, et al. Randomized trial on the effects of high-dose zopiclone on OSA severity, upper airway physiology, and alertness. Chest. 2020 Jul;158(1):374–385. doi: 10.1016/j.chest.2020.02.057
   PubMed Web of Science ®Google Scholar
• Scharner V, Hasieber L, Sönnichsen A, et al. Efficacy and safety of Z-substances in the management of insomnia in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing. BMC Geriatr. 2022 Feb 1;22(1):87. doi: 10.1186/s12877-022-02757-6
   PubMed Web of Science ®Google Scholar
• Edwards BA, Sands SA, Eckert DJ, et al. Acetazolamide improves loop gain but not the other physiological traits causing obstructive sleep apnoea. J Physiol. 2012 Mar 1;590(5):1199–1211. doi: 10.1113/jphysiol.2011.223925
   PubMed Web of Science ®Google Scholar
• Eskandari D, Zou D, Karimi M, et al. Zonisamide reduces obstructive sleep apnoea: a randomised placebo-controlled study. Eur Respir J. 2014;44(1):140–149. doi: 10.1183/09031936.00158413
   PubMed Web of Science ®Google Scholar
• Fischer R, Lang SM, Leitl M, et al. Theophylline and acetazolamide reduce sleep-disordered breathing at high altitude. Eur Respir J. 2004;23(1):47–52. doi: 10.1183/09031936.03.00113102
   PubMed Web of Science ®Google Scholar
• Hedner J, Stenlöf K, Zou D, et al. A randomized controlled clinical trial exploring safety and tolerability of sulthiame in sleep apnea. Am J Respir Crit Care Med. 2022 Jun 15;205(12):1461–1469. doi: 10.1164/rccm.202109-2043OC
   PubMed Web of Science ®Google Scholar
• Schmickl CN, Landry SA, Orr JE, et al. Acetazolamide for OSA and Central Sleep Apnea: A Comprehensive Systematic Review and Meta-Analysis. Chest. 2020 Dec;158(6):2632–2645. doi: 10.1016/j.chest.2020.06.078
   PubMed Web of Science ®Google Scholar
• Eskandari D, Zou D, Grote L, et al. Acetazolamide reduces blood pressure and sleep-disordered breathing in patients with hypertension and obstructive sleep apnea: a randomized controlled trial. J Clin Sleep Med. 2018;14(3):309–317. doi: 10.5664/jcsm.6968
   PubMed Web of Science ®Google Scholar
• Anam M, Maharjan S, Amjad Z, et al. Efficacy of semaglutide in treating obesity: a systematic review of randomized controlled trials (RCTs). Cureus. 2022. doi: 10.7759/cureus.32610.
   Google Scholar
• Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes. JAMA. 2022;327(2):138. doi: 10.1001/jama.2021.23619
   PubMed Web of Science ®Google Scholar
• Gaisl T, Turnbull CD, Weimann G, et al. BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN). Eur Respir J. 2021 Nov;58(5):2101937. doi: 10.1183/13993003.01937-2021
   PubMed Web of Science ®Google Scholar
• Osman AM, Mukherjee S, Altree TJ, et al. Topical Potassium channel blockage improves pharyngeal collapsibility: a translational, placebo-controlled trial. Chest. 2023 Apr;163(4):953–965. doi: 10.1016/j.chest.2022.11.024
   PubMed Web of Science ®Google Scholar
• Osman AM, Altree TJ, Eckert DJ. The scent of love is in the air(way): a potential drug target for sleep apnea? Sleep. 2023;46(4). doi: 10.1093/sleep/zsad019
   PubMed Web of Science ®Google Scholar
• Segsarnviriya C, Chumthong R, Mahakit P. Effects of intranasal steroids on continuous positive airway pressure compliance among patients with obstructive sleep apnea. Sleep Breath. 2021 Sep;25(3):1293–1299. doi: 10.1007/s11325-020-02236-5
   PubMed Web of Science ®Google Scholar
• Perger E, Bertoli S, Lombardi C. Pharmacotherapy for obstructive sleep apnea: targeting specific pathophysiological traits. Expert Rev Respir Med. 2023 Jul;17(8):663–673. doi: 10.1080/17476348.2023.2241353
   PubMed Web of Science ®Google Scholar
• Schweitzer PK. Chapter 46 - drugs that disturb sleep and wakefulness. In: Kryger M, Roth T Dement W, editors Principles and practice of sleep medicine. Fifth ed. Philadelphia: W.B. Saunders; 2011. p. 542–560.
   Google Scholar
• Wichniak A, Wierzbicka A, Walęcka M, et al. Effects of antidepressants on sleep. Curr Psychiatry Rep. 2017 Aug 9;19(9):63. doi: 10.1007/s11920-017-0816-4
   PubMed Web of Science ®Google Scholar
• Cheng JY. Serotonin reuptake inhibitors in obstructive sleep apnea: associations in people with and without epilepsy. Neurol Res Int. 2018;2018:7247605. doi: 10.1155/2018/7247605
   PubMed Web of Science ®Google Scholar
• Robillard R, Saad M, Ray LB, et al. Selective serotonin reuptake inhibitor use is associated with worse sleep-related breathing disturbances in individuals with depressive disorders and sleep complaints: a retrospective study. J Clin Sleep Med. 2021;17(3):505–513. doi: 10.5664/jcsm.8942
   PubMed Web of Science ®Google Scholar
• Thomson LDJ, Landry SA, Joosten SA, et al. A single dose of noradrenergic/serotonergic reuptake inhibitors combined with an antimuscarinic does not improve obstructive sleep apnoea severity. Physiol Rep. 2022 Aug;10(16):e15440. doi: 10.14814/phy2.15440
   PubMed Web of Science ®Google Scholar
• Taranto-Montemurro L, Messineo L, Sands SA, et al. The combination of atomoxetine and oxybutynin greatly reduces obstructive sleep apnea severity. A randomized, placebo-controlled, double-blind crossover trial. Am J Respir Crit Care Med. 2019 May 15;199(10):1267–1276. doi: 10.1164/rccm.201808-1493OC
   PubMed Web of Science ®Google Scholar
• Lim R, Carberry JC, Wellman A, et al. Reboxetine and hyoscine butylbromide improve upper airway function during nonrapid eye movement and suppress rapid eye movement sleep in healthy individuals. Sleep. 2019 Apr 1;42(4). doi: 10.1093/sleep/zsy261
   Web of Science ®Google Scholar
• Taranto-Montemurro L, Pho H, White DP. Development of a combination of noradrenergic and antimuscarinic drugs for the treatment of obstructive sleep apnea: challenges and progress. Front Sleep. 2023;2. doi: 10.3389/frsle.2023.1148282
   Google Scholar
• Messineo L, Carter SG, Taranto-Montemurro L, et al. Addition of zolpidem to combination therapy with atomoxetine-oxybutynin increases sleep efficiency and the respiratory arousal threshold in obstructive sleep apnoea: a randomized trial. Respirology. 2021 Sep;26(9):878–886. doi: 10.1111/resp.14110
   PubMed Web of Science ®Google Scholar
• Messineo L, Eckert DJ, Lim R, et al. Zolpidem increases sleep efficiency and the respiratory arousal threshold without changing sleep apnoea severity and pharyngeal muscle activity. J Physiol. 2020 Oct;598(20):4681–4692. doi: 10.1113/JP280173
   PubMed Web of Science ®Google Scholar
• Corser B, Eves E, Warren-McCormick J, et al. Effects of atomoxetine plus a hypnotic on obstructive sleep apnea severity in patients with a moderately collapsible pharyngeal airway. J Clin Sleep Med. 2023 Jun 1;19(6):1035–1042. doi: 10.5664/jcsm.10464
   PubMed Web of Science ®Google Scholar
• Mogavero MP, Silvani A, Lanza G, et al. Targeting orexin receptors for the treatment of insomnia: from physiological mechanisms to Current clinical evidence and recommendations. Nat Sci Sleep. 2023;15:17–38. doi: 10.2147/NSS.S201994
   PubMed Web of Science ®Google Scholar
• Zheng Y, Lv T, Wu J, et al. Trazodone changed the polysomnographic sleep architecture in insomnia disorder: a systematic review and meta-analysis. Sci Rep. 2022 Aug 24;12(1):14453. doi: 10.1038/s41598-022-18776-7
   PubMed Web of Science ®Google Scholar
• Chen CY, Chen CL, Yu CC. Trazodone improves obstructive sleep apnea after ischemic stroke: a randomized, double-blind, placebo-controlled, crossover pilot study. J Neurol. 2021 Aug;268(8):2951–2960. doi: 10.1007/s00415-021-10480-2
   PubMed Web of Science ®Google Scholar
• Eckert DJ, Malhotra A, Wellman A, et al. Trazodone increases the respiratory arousal threshold in patients with obstructive sleep apnea and a low arousal threshold. Sleep. 2014;37(4):811–819. doi: 10.5665/sleep.3596
   PubMed Web of Science ®Google Scholar
• Smales ET, Edwards BA, Deyoung PN, et al. Trazodone effects on obstructive sleep apnea and non-REM arousal threshold. Ann Am Thorac Soc. 2015 May;12(5):758–764. doi: 10.1513/AnnalsATS.201408-399OC
   PubMed Web of Science ®Google Scholar
• Graf LC, Furian M, Bitos K, et al. Effect of altitude and acetazolamide on sleep and nocturnal breathing in healthy lowlanders 40 y of age or older. Data from a randomized trial. Sleep. 2023 Apr 12;46(4). doi: 10.1093/sleep/zsac269
   Web of Science ®Google Scholar
• Ni Y-N, Yang H, Thomas RJ. The role of acetazolamide in sleep apnea at sea level: a systematic review and meta-analysis. J Clin Sleep Med. 2021;17(6):1295–1304. doi: 10.5664/jcsm.9116
   PubMed Web of Science ®Google Scholar
• Ni YN, Holzer RC, Thomas RJ. Acute and long-term effects of acetazolamide in presumed high loop gain sleep apnea. Sleep Med. 2023 Jul;107:137–148. doi: 10.1016/j.sleep.2023.04.010
   PubMed Web of Science ®Google Scholar
• Erdő F, Bors LA, Farkas D, et al. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull. 2018;143:155–170. doi: 10.1016/j.brainresbull.2018.10.009
   PubMed Web of Science ®Google Scholar
• Keller L-A, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res. 2022;12(4):735–757. doi: 10.1007/s13346-020-00891-5
   PubMed Web of Science ®Google Scholar
• Baillieul S, Tamisier R, Eckert DJ, et al. Current knowledge and perspectives for pharmacological treatment in OSA. Arch Bronconeumol. 2022 Oct;58(10):681–684. doi: 10.1016/j.arbres.2021.12.013
   PubMed Web of Science ®Google Scholar
• St-Onge MP, Tasali E. Weight Loss Is Integral to Obstructive Sleep Apnea Management. Ten-Year Follow-up in Sleep AHEAD. Am J Respir Crit Care Med. 2021 Jan 15;203(2):161–162. doi: 10.1164/rccm.202007-2906ED
   PubMed Web of Science ®Google Scholar
• Turner AD, Ong JC, Jones AL, et al. Neurocognitive functioning in comorbid insomnia and sleep apnea patients is better after positive airway pressure therapy, but worse after cognitive behavioral therapy for insomnia: exploratory analysis of cognitive outcomes from the multidisciplinary approach to the treatment of insomnia and comorbid sleep apnea study. Sleep. 2023 Aug 14;46(8). doi: 10.1093/sleep/zsad128
   PubMed Web of Science ®Google Scholar
• Tu AY, Crawford MR, Dawson SC, et al. A randomized controlled trial of cognitive behavioral therapy for insomnia and PAP for obstructive sleep apnea and comorbid insomnia: effects on nocturnal sleep and daytime performance. J Clin Sleep Med. 2022 Mar 1;18(3):789–800. doi: 10.5664/jcsm.9696
   PubMed Web of Science ®Google Scholar